NCT07100106 2026-04-21
MoonROSE
Genentech, Inc.
Phase 1/2 Recruiting
Clinical Trials
20 trialsNCT07541079 2026-04-21
A Study Evaluating Adherence, Tolerability, and Patient Reported Outcomes of Giredestrant in Participants With ER+/HER2- Early Breast Cancer Who Are Intolerant to Adjuvant Aromatase Inhibitor Therapy (novERA Breast Cancer)
Genentech, Inc.
Phase 3 Not yet recruiting
NCT05296798 2026-04-16
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04802759 2026-04-13
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Hoffmann-La Roche
Phase 1/2 Recruiting
NCT05634499 2026-04-13
EndomERA
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT06065748 2026-04-06
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Recruiting
NCT07214662 2026-04-03
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-0587 as a Monotherapy and in Combination With Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer
Genentech, Inc.
Phase 1 Recruiting
NCT04486352 2026-04-01
EndoMAP
Alliance Foundation Trials, LLC.
Phase 1/2 Recruiting
NCT04576455 2026-03-20
A Study Evaluating the Efficacy and Safety of Giredestrant Compared With Physician's Choice of Endocrine Monotherapy in Participants With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (acelERA Breast Cancer)
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT05659563 2026-03-19
EMPRESS
MedSIR
Phase 2 Completed
NCT04931342 2026-03-10
BOUQUET
Hoffmann-La Roche
Phase 2 Active not recruiting
NCT05708235 2026-03-05
MiRaDoR
MedSIR
Phase 2 Recruiting
NCT05896566 2026-02-24
PREcoopERA
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT04546009 2026-02-20
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04961996 2026-02-20
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03332797 2026-02-13
A Study of GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer
Genentech, Inc.
Phase 1 Active not recruiting
NCT05306340 2026-01-30
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)
Genentech, Inc.
Phase 3 Active not recruiting
NCT06259929 2025-02-18
Neo-AGILE
Fondazione Oncotech
Phase 2 Recruiting
NCT03916744 2023-03-10
A Study of Giredestrant (GDC-9545) in Postmenopausal Women With Stage I-III Operable, Estrogen Receptor-Positive Breast Cancer
Genentech, Inc.
Phase 1 Completed
NCT04436744 2023-02-02
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Giredestrant Plus Palbociclib Compared With Anastrozole Plus Palbociclib for Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Untreated Early Breast Cancer (coopERA Breast Cancer)
Hoffmann-La Roche
Phase 2 Completed